Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 1/2017

01-02-2017 | Therapeutic Aspects in Autoimmunity

Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?

Authors: Mohammad Hassan A. Noureldine, Ali A. Haydar, Ahmad Berjawi, Rody Elnawar, Ahmad Sweid, Munther A. Khamashta, Graham R. V. Hughes, Imad Uthman

Published in: Immunologic Research | Issue 1/2017

Login to get access

Abstract

Headaches have been extensively reported in Antiphospholipid syndrome (APS)/Antiphospholipid antibodies (aPL)-positive patients. The aim of this study was to highlight the prevalence of headaches among APS/aPL-positive patients and discuss its association with laboratory, clinical and imaging findings. We searched the literature through Google Scholar and PubMed for publications on the epidemiology, pathogenesis, laboratory, imaging and clinical findings, and management of headaches in APS/aPL-positive patients. The following keywords were used: Antiphospholipid, Hughes syndrome, anticardiolipin, lupus anticoagulant, anti-β2 glycoprotein I, headache, migraine, tension, and cluster. All reports published between 1969 and 2015 were included. Migraine is the most commonly reported type of headache in APS/aPL-positive patients. Thrombotic and platelet dysfunction hypotheses have been studied to uncover the pathogenic role of aPL in the development of headaches. Several studies are reporting higher levels of aPL in primary and secondary APS migraineurs, but only few reached statistical significance. Migraine patients without clinical signs/symptoms of cerebral infarction rarely show positive imaging findings. Digital subtraction angiography shows promise in demonstrating small vascular lesions otherwise not detected on computed tomography, magnetic resonance imaging, or cerebral angiograms. Although it may be solitary and harmless in many cases, the deleterious effect of migraine on the quality of life of APS patients prompts rapid diagnosis and proper management. An anticoagulation trial is advisable in APS patients with migraine as many cases of severe, refractory migraine resolved with anticoagulation therapy. The profile of migraine headaches discussed in this study permits its candidacy for inclusion in future APS classification criteria.
Literature
1.
Hughes G, Harris N, Gharavi A. The anticardiolipin syndrome. J Rheumatol. 1986;13(3):486–9.PubMed
2.
Merashli M, Noureldine MHA, Uthman I, Khamashta M. Antiphospholipid syndrome: an update. Eur J Clin Invest. 2015;45(6):653–62.PubMedCrossRef
3.
Khamashta M, Bertolaccini M, Hughes G. Antiphospholipid (Hughes) syndrome. Autoimmunity. 2004;37(4):309–12.PubMedCrossRef
4.
Uthman IW, Khamashta MA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol. 2006;33(12):2379.PubMed
5.
6.
Tenedios F, Erkan D, Lockshin M. Cardiac involvement in the antiphospholipid syndrome. Lupus. 2005;14(9):691–6.PubMedCrossRef
7.
Kaushik S, Federle M, Schur P, Krishnan M, Silverman S, Ros P. Abdominal thrombotic and ischemic manifestations of the antiphospholipid antibody syndrome: CT findings in 42 patients. Radiology. 2001;218(3):768–71.PubMedCrossRef
8.
Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology. 2007;46(11):1641–7.PubMedCrossRef
9.
10.
André M, Delèvaux I, Amoura Z, Corbi P, Courthaliac C, Aumaître O, et al. Ovarian vein thrombosis in the antiphospholipid syndrome. Arthritis Rheum. 2004;50(1):183–6.PubMedCrossRef
11.
Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol. 2003;101(6):1333–44.PubMed
12.
Noureldine M, Khamashta M, Merashli M, Sabbouh T, Hughes G, Uthman I. Musculoskeletal manifestations of the antiphospholipid syndrome. Lupus. 2016;25(5):451–62.CrossRef
13.
14.
Hughes G. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J. 1983;287(6399):1088.CrossRef
15.
Rodrigues C, Carvalho J, Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest. 2010;40(4):350–9.PubMedCrossRef
16.
Uthman I, Noureldine M, Berjawi A, Skaf M, Haydar A, Merashli M, et al. Hughes syndrome and Multiple sclerosis. Lupus. 2015;24(2):115–21.PubMedCrossRef
17.
Cervera R, Boffa M, Khamashta M, Hughes G. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus. 2009;18(10):889–93.PubMedCrossRef
18.
Shuaib A, Barklay L, Lee M, Suchowersky O. Migraine and anti-phospholipid antibodies. Headache. 1989;29(1):42–5.PubMedCrossRef
19.
Sanna G, Bertolaccini M, Cuadrado M, Laing H, Khamashta M, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003;30(5):985–92.PubMed
20.
Asherson R, Mercey D, Phillips G, Sheehan N, Gharavi A, Harris E, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis. 1987;46(8):605–11.PubMedPubMedCentralCrossRef
21.
Levine S, Deegan M, Futrell N, Welch K. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology. 1990;40(8):1181–9.PubMedCrossRef
22.
Hering R, Couturier E, Steiner T, Asherson R, Clifford RF. Anticardiolipin antibodies in migraine. Cephalalgia. 1991;11(1):19–21.PubMedCrossRef
23.
Gharavi A, Harris E, Asherson R, Hughes G. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis. 1987;46(1):1–6.PubMedPubMedCentralCrossRef
24.
Hering R, Couturier E, Asherson R, Steiner T. Anticardiolipin antibodies in cluster headache. Cephalalgia. 1991;11(2):101–2.PubMedCrossRef
25.
Iñiguez C, Pascual C, Pardo A, Martinez-Castrillo J, Alvarez-Cermeño J. Antiphospholipid antibodies in migraine. Headache. 1991;31(10):666–8.PubMedCrossRef
26.
Robbins L. Migraine and anticardiolipin antibodies-case reports of 13 patients, and the prevalence of antiphospholipid antibodies in migraineurs. Headache. 1991;31(8):537–9.PubMedCrossRef
27.
Markus H, Hopkinson N. Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids. J Neurol. 1992;239(1):39–42.PubMedCrossRef
28.
Montalbán J, Cervera R, Font J, Ordi J, Vianna J, Haga H, et al. Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus. Neurology. 1992;42(3 Pt 1):681–2.PubMedCrossRef
29.
Hinse P, Schulz A, Haag F, Carvajal-Lizano M, Thie A. Anticardiolipin antibodies in oculocerebral ischaemia and migraine: prevalence and prognostic value. Cerebrovasc Dis. 1993;3(3):168–73.CrossRef
30.
Sfikakis PP, Mitsikostas DD, Manoussakis MN, Foukaneli D, Moutsopoulos HM. Headache in systemic lupus erythematosus: a controlled study. Br J Rheumatol. 1998;37(3):300–3.PubMedCrossRef
31.
Tietjen G, Day M, Norris L, Aurora S, Halvorsen A, Schultz L, et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study. Neurology. 1998;50(5):1433–40.PubMedCrossRef
32.
Fernandez-Nebro A, Palacios-Munoz R, Gordillo J, Abarca-Costalago M, De Haro-Liger M, Rodriguez-Andreu J, et al. Chronic or recurrent headache in patients with systemic lupus erythematosus: a case control study. Lupus. 1999;8(2):151–7.PubMedCrossRef
33.
Verrotti A, Cieri F, Pelliccia P, Morgese G, Chiarelli F. Lack of association between antiphospholipid antibodies and migraine in children. Int J Clin Lab Res. 2000;30(2):109–11.PubMedCrossRef
34.
Intiso D, Crociani P, Fogli D, Grandone E, Cappucci G, Di Rienzo F, et al. Occurrence of factor V Leiden mutation (Arg506Gln) and anticardiolipin antibodies in migraine patients. Neurol Sci. 2002;22(6):455–8.PubMedCrossRef
35.
Avcin T, Markelj G, Niksic V, Rener-Primec Z, Cucnik S, Zupancic M, et al. Estimation of antiphospholipid antibodies in a prospective longitudinal study of children with migraine. Cephalalgia. 2004;24(10):831–7.PubMedCrossRef
36.
Cavestro C, Micca G, Molinari F, Bazzan M, DI Pietrantonj C, Aloi R, et al. Migraineurs show a high prevalence of antiphospholipid antibodies. J Thromb Haemost. 2011;9(7):1350–4.PubMedCrossRef
37.
Stojanovich L, Kontic M, Smiljanic D, Djokovic A, Stamenkovic B, Marisavljevic D. Association between non-thrombotic neurological and cardiac manifestations in patients with antiphospholipid syndrome. Clin Exp Rheumatol. 2013;31(5):756–60.PubMed
38.
Sanna G, Bertolaccini M, Cuadrado M, Khamashta M, Hughes G. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology. 2003;42(2):200–13.PubMedCrossRef
39.
40.
Hughes G. Migraine, memory loss, and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad Med J. 2003;79(928):81–3.PubMedPubMedCentralCrossRef
41.
42.
Pilarska E, Lemka M, Bakowska A. Antiphospholipid antibodies in children with migraine. Neurol Neurochir Pol. 2006;40(4):291–6.PubMed
43.
Angelini L, Zibordi F, Zorzi G, Nardocci N, Caporali R, Ravelli A, et al. Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. Neuropediatrics. 1996;27(3):149–53. doi:10.​1055/​s-2007-973766.PubMedCrossRef
44.
Hogan M, Brunet D, Ford P, Lillicrap D. Lupus anticoagulant, antiphospholipid antibodies and migraine. Can J Neurol Sci. 1988;15(4):420–5.PubMed
45.
46.
Tsakiris D, Kappos L, Reber G, Marbet G, Le Floch-Rohr J, Roux E, et al. Lack of association between antiphospholipid antibodies and migraine. Thromb Haemost. 1993;69(5):415–7.PubMed
47.
48.
49.
Schürks M, Rist P, Bigal M, Buring J, Lipton R, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914.PubMedPubMedCentralCrossRef
50.
Kruit M, van Buchem M, Launer L, Terwindt G, Ferrari M. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia. 2010;30(2):129–36.PubMedPubMedCentral
51.
Kurth T, Slomke M, Kase C, Cook N, Lee I, Gaziano J, et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology. 2005;64(6):1020–6.PubMedCrossRef
52.
Fields R, Toubbeh H, Searles R, Bankhurst A. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol. 1989;16(5):623–5.PubMed
53.
Tzourio C, Kittner S, Bousser M, Alpérovitch A. Migraine and stroke in young women. Cephalalgia. 2000;20(3):190–9.PubMedCrossRef
54.
Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.PubMedCrossRef
55.
Liang M, Corzillius M, Bae S, Lew R, Fortin P, Gordon C, et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599–608.CrossRef
56.
Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsänoja R, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Care Res. 2001;45(5):419–23.CrossRef
57.
Brey R, Holliday S, Saklad A, Navarrete M, Hermosillo-Romo D, Stallworth C, et al. Neuropsychiatric syndromes in lupus Prevalence using standardized definitions. Neurology. 2002;58(8):1214–20.PubMedCrossRef
58.
Sibbitt WL, Brandt JR, Johnson CR, Maldonado ME, Patel SR, Ford CC, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol. 2002;29(7):1536–42.PubMed
59.
Hanly JG, McCurdy G, Fougere L, Douglas J-A, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol. 2004;31(11):2156–62.PubMed
60.
Love P, Santoro S. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med. 1990;112(9):682–98.PubMedCrossRef
61.
62.
Anzola G, Dalla Volta G, Balestrieri G. Headache in patients with systemic lupus erythematosus: clinical and telethermographic findings. Arch Neurol. 1988;45(10):1061–2.PubMedCrossRef
63.
Asherson R, Khamashta M, Gil A, Vazquez J, Chan O, Baguley E, et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med. 1989;86(4):391–9.PubMedCrossRef
64.
Hess D. Stroke associated with antiphospholipid antibodies. Stroke. 1992;23(2 Suppl):I23–8.PubMed
65.
Czlonkowska A, Meurer M, Palasik W, Baranska-Gieruszczak M, Mendel T, Wierzchowska E. Anticardiolipin antibodies, a disease marker for ischemic cerebrovascular events in a younger patient population? Acta Neurol Scand. 1992;86(3):304–7.PubMedCrossRef
66.
Vrethem M, Ernerudh J, Lindström F, Olsson J. Cerebral ischemia associated with anticardiolipin antibodies. Acta Neurol Scand. 1992;85(6):412–7.PubMedCrossRef
67.
Weinberger J. Stroke and migraine. Curr Cardiol Rep. 2008;1(9):13–9.
68.
69.
Boey M, Colaco C, Gharavi A, Elkon K, Loizou S, Hughes G. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J. 1983;287(6398):1021–3.CrossRef
70.
Glueck H, Kant K, Weiss M, Pollak V, Miller M, Coots M. Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants. Arch Intern Med. 1985;145(8):1389–95.PubMedCrossRef
71.
Gastineau D, Kazmier F, Nichols W, Bowie E. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol. 1985;19(3):265–75.PubMedCrossRef
72.
Alving B, Baldwin P, Richards R, Jackson B. The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants. Thromb Haemost. 1985;54(3):709–12.PubMed
73.
Harris E, Chan J, Asherson R, Aber V, Gharavi A, Hughes G. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med. 1986;146(11):2153–6.PubMedCrossRef
74.
Damasio H, Beck D. Migraine thrombocytopenia, and serotonin metabolism. Lancet. 1978;1(8058):240–2.PubMedCrossRef
75.
Lee SL, Miotti AB. Disorders of hemostatic function in patients with systemic lupus erythematosus. In: Seminars in arthritis and rheumatism, vol 3. Elsevier; 1975.
76.
Dvilansky A, Rishpon S, Nathan I, Zolotow Z, Korczyn A. Release of platelet 5-hydroxytryptamine by plasma taken from patients during and between migraine attacks. Pain. 1976;2(3):315–8.PubMedCrossRef
77.
Gladman D, Urowitz M, Tozman E, Glynn M. Haemostatic abnormalities in systemic lupus erythematosus. Q J Med. 1983;52(207):424–33.PubMed
78.
Karpatkin S, Siskind G. In vitro detection of platelet antibody in patients with idiopathic thrombocytopenic purpura and systemic lupus erythematosus. Blood. 1969;33(6):795–812.PubMed
79.
Harris E, Gharavi A, Hegde U, Derue G, Morgan S, Englert H, et al. Anticardiolipin antibodies in autoimmune thrombocytopenic purpura. Br J Haematol. 1985;59(2):231–4.PubMedCrossRef
80.
McCarren TJ, Hitzemann R, Smith R, Glueck C. Membranes and migraine. Cephalalgia. 1985;5(3 suppl):548–9.
81.
Oxman T, Hitzemann R, Smith R. Platelet membrane lipid composition and the frequency of migraine. Headache. 1982;22(6):261–7.PubMedCrossRef
82.
Shattil S, Cooper R. Role of membrane lipid composition, organization, and fluidity in human platelet function. Prog Hemost Thromb. 1978;4:59–86.PubMed
83.
84.
Briley D, Coull B, Goodnight S Jr. Neurological disease associated with antiphospholipid antibodies. Ann Neurol. 1989;25(3):221–7.PubMedCrossRef
85.
Gallo P, Sivieri S, Ferrarini A, Giometto B, Ruffatti A, Ritter E, et al. Cerebrovascular and neurological disorders associated with antiphospholipid antibodies in CSF and serum. J Neurol Sci. 1994;122(1):97–101.PubMedCrossRef
86.
Levine SR, Joseph R, D’Andrea G, Welch K. Migraine and the lupus anticoagulant case reports and review of the literature. Cephalalgia. 1987;7(2):93–9.PubMedCrossRef
87.
Williams F, Cherkas L, Bertolaccini M, Murru V, Surdulescu G, Hughes G, et al. Migraine and antiphospholipid antibodies: no association found in migraine-discordant monozygotic twins. Cephalalgia. 2008;28(10):1048–52.PubMedCrossRef
88.
89.
Cervera R, Khamashta M, Font J, Sebastiani G, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine. 1993;72(2):113–24.PubMedCrossRef
90.
Sanna G, D’Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am. 2006;32(3):465–90.PubMedCrossRef
91.
Ciubotaru C, Esfahani F, Benedict R, Wild L, Baer A. Chorea and rapidly progressive subcortical dementia in antiphospholipid syndrome. J Clin Rheumatol. 2002;8(6):332–9.PubMedCrossRef
92.
Gutrecht J, Kattwinkel N, Stillman M. Retinal migraine, chorea, and retinal artery thrombosis in a patient with primary antiphospholipid antibody syndrome. J Neurol. 1991;238(1):55–6.PubMedCrossRef
93.
Silvestrini M, Matteis M, Troisi E, Cupini L, Zaccari G, Bernardi G. Migrainous stroke and the antiphospholipid antibodies. Eur Neurol. 1994;34(6):316–9.PubMedCrossRef
94.
Hughes GR, Cuadrado M, Khamashta M, Sanna G. Headache and memory loss: rapid response to heparin inthe antiphospholipid syndrome. Lupus. 2001;10(11):778.PubMedCrossRef
95.
Silvestrini M, Cupini L, Matteis M, De Simone R, Bernardi G. Migraine in patients with stroke and antiphospholipid antibodies. Headache. 1993;33(8):421–6.PubMedCrossRef
96.
Kim JH, Choi C-G, Choi S-J, Lee HK, Suh DC. Primary antiphospholipid antibody syndrome: neuroradiologic findings in 11 patients. Korean J Radiol. 2000;1(1):5–10.PubMedPubMedCentralCrossRef
97.
Zhu D, Fu J, Zhang Y, Li S, Zhang G, Guan Y, et al. Neurological antiphospholipid syndrome: clinical, neuroimaging, and pathological characteristics. J Neurol Sci. 2014;346(1–2):138–44.PubMedCrossRef
98.
Erkan D, Aguiar C, Andrade D, Cohen H, Cuadrado M, Danowski A, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685–96.PubMedCrossRef
99.
Hughes GR. Hughes Syndrome (the antiphospholipid syndrome): ten clinical lessons. Autoimmun Rev. 2008;7(3):262–6.PubMedCrossRef
100.
Thonnard-Neumann E. Migraine therapy with heparin: pathophysiologic basis. Headache. 1977;16(6):284–92.PubMedCrossRef
101.
Morales-Asín F, Iñiguez C, Cornudella R, Mauri J, Espada F, Mostacero E. Patients with acenocoumarol treatment and migraine. Headache. 2000;40(1):45–7.PubMedCrossRef
102.
Rahimtoola H, Egberts A, Buurma H, Tijssen C, Leufkens H. Reduction in the intensity of abortive migraine drug use during coumarin therapy. Headache. 2001;41(8):768–73.PubMedCrossRef
103.
der Heijden Wammes-van. E, Tijssen C, van’t Hoff A, Egberts A. A thromboembolic predisposition and the effect of anticoagulants on migraine. Headache. 2004;44(5):399–402.CrossRef
104.
Asherson R, Giampaulo D, Singh S, Sulman L. Dramatic response of severe headaches to anticoagulation in a patient with antiphospholipid syndrome. J Clin Rheumatol. 2007;13(3):173–4.PubMedCrossRef
105.
King E, Odette W. Complex migraine with subtherapeutic INR in antiphospholipid syndrome. Am J Med. 2012;125(11):9–10.CrossRef
106.
Mayer M, Cerovec M, Rados M, Cikes N. Antiphospholipid syndrome and central nervous system. Clin Neurol Neurosurg. 2010;112(7):602–8.PubMedCrossRef
107.
D’Andrea G, Bussone G, Allais G, Aguggia M, D’Onofrio F, Maggio M, et al. Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurolog Sci. 2009;30:S121–4.CrossRef
Metadata
Title
Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?
Authors
Mohammad Hassan A. Noureldine
Ali A. Haydar
Ahmad Berjawi
Rody Elnawar
Ahmad Sweid
Munther A. Khamashta
Graham R. V. Hughes
Imad Uthman
Publication date
01-02-2017
Publisher
Springer US
Published in
Immunologic Research / Issue 1/2017
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-016-8831-9

Other articles of this Issue 1/2017

Immunologic Research 1/2017 Go to the issue

Environment and Autoimmunity

Guillain–Barré syndrome in Colombia: where do we stand now?

Mechanism in Autoimmunity

Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study

Environment and Autoimmunity

Autoimmune reaction after anti-tetanus vaccination—description of four cases and review of the literature

Therapeutic Aspects in Autoimmunity

Glaucoma: recent advances in the involvement of autoimmunity

Environment and Autoimmunity

Severe manifestations of autoimmune syndrome induced by adjuvants (Shoenfeld’s syndrome)

Mechanism in Autoimmunity

Primary Sjögren’s syndrome: clinical phenotypes, outcome and the development of biomarkers